Skip to content
drillr.ai
Sign up

01061.HK

Essex Bio-Technology Limited

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

HKD 2.21
+3.76%
Ask drillr

  • Aug 5, 2026, 13:09 UTC

    Essex Bio-Technology declared an interim dividend of HK$0.05 per share for the six months ended June 2026, down from HK$0.07 in the prior year period.

    Source:

  • Aug 5, 2026, 13:09 UTC

    Essex Bio-Technology reported interim results for the six months ended June 2026, with revenue of HK$785 million, down 10.5% year-on-year, and net profit of HK$111 million, down 32.2%.

    Source:

  • Jul 23, 2026, 09:14 UTC

    Yisheng Bio (01061) entered into a strategic cooperation framework agreement with Kureha Medical to expand their collaboration in regenerative medicine and wound repair across China, Southeast Asia, and Japan.

    Source:

  • Jul 23, 2026, 09:13 UTC

    Yisheng Bio and Japan Gunze Medical signed a strategic cooperation framework agreement to expand their commercial partnership and establish a global collaboration platform for regenerative medicine and wound repair.

    Source: